ArticleScientific reports2026

Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.

Zhiwei Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.